Switch theme
Sign up to access all valuation multiples
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
2010
n/a
LTM Revenue n/a
LTM EBITDA n/a
$60.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anatolia Geneworks has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Anatolia Geneworks achieved revenue of $13.9M and an EBITDA of -$1.5M.
Anatolia Geneworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anatolia Geneworks valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.3M | $13.9M | XXX | XXX | XXX |
| Gross Profit | $5.9M | $5.0M | XXX | XXX | XXX |
| Gross Margin | 94% | 36% | XXX | XXX | XXX |
| EBITDA | -$2.1M | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | -34% | -11% | XXX | XXX | XXX |
| Net Profit | $8.7M | -$3.6M | XXX | XXX | XXX |
| Net Margin | 139% | -26% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Anatolia Geneworks's stock price is TRY 11 (or $0).
Anatolia Geneworks has current market cap of TRY 2.5B (or $66.1M), and EV of TRY 2.3B (or $60.8M).
See Anatolia Geneworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.8M | $66.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Anatolia Geneworks has market cap of $66.1M and EV of $60.8M.
Anatolia Geneworks's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Anatolia Geneworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Anatolia Geneworks and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $60.8M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | -41.3x | XXX | XXX | XXX |
| P/E | -11.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -22.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnatolia Geneworks's NTM/LTM revenue growth is n/a
Anatolia Geneworks's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Anatolia Geneworks's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Anatolia Geneworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Anatolia Geneworks and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 122% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 60% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anatolia Geneworks acquired XXX companies to date.
Last acquisition by Anatolia Geneworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Anatolia Geneworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Anatolia Geneworks founded? | Anatolia Geneworks was founded in 2010. |
| Where is Anatolia Geneworks headquartered? | Anatolia Geneworks is headquartered in Turkey. |
| Is Anatolia Geneworks publicy listed? | Yes, Anatolia Geneworks is a public company listed on IST. |
| What is the stock symbol of Anatolia Geneworks? | Anatolia Geneworks trades under ANGEN ticker. |
| When did Anatolia Geneworks go public? | Anatolia Geneworks went public in 2021. |
| Who are competitors of Anatolia Geneworks? | Similar companies to Anatolia Geneworks include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Anatolia Geneworks? | Anatolia Geneworks's current market cap is $66.1M |
| What is the current revenue growth of Anatolia Geneworks? | Anatolia Geneworks revenue growth between 2023 and 2024 was 122%. |
| Is Anatolia Geneworks profitable? | Yes, Anatolia Geneworks is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
